SCHEMBL6515665

SCHEMBL6515665

Cc1cc(C(=O)O)c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4ccccc4F)cc32)[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 3/20 0.47
AURKA O14965 4/20 0.47
KDR P35968 7/20 0.46
FGFR1 P11362 5/20 0.46
PDGFRB P09619 5/20 0.46
EGFR P00533 1/20 0.46
SRC P12931 6/20 0.45
ALK Q9UM73 3/20 0.44
TLK2 Q86UE8 1/20 0.43
PRKDC P78527 1/20 0.43
PDPK1 O15530 2/20 0.43
FYN P06241 2/20 0.43
YES1 P07947 1/20 0.43
RET P07949 3/20 0.43
CSF1R P07333 2/20 0.43
FGFR3 P22607 2/20 0.43
MAPK1 P28482 2/20 0.43
FLT4 P35916 2/20 0.43
FLT3 P36888 2/20 0.43
MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6519857 0.88 AURKA (0.56) FLT1AURKAKDRFGFR1PDGFRB
SCHEMBL6514642 0.87 AKT2 (0.54) AURKAKDRFGFR1PDGFRBEGFR
SCHEMBL6267000 0.85 ALK (0.64) AURKAKDRFGFR1PDGFRBEGFR
SCHEMBL147703 0.85 KDR (0.55) FLT1AURKAKDRFGFR1PDGFRB
SCHEMBL145575 0.82 PDGFRB (0.50) KDRFGFR1PDGFRBEGFRSRC
SCHEMBL6523443 0.82 RET (0.49) FLT1AURKAKDRFGFR1PDGFRB
SCHEMBL146649 0.81 PDGFRB (0.41) AURKAKDRFGFR1PDGFRBEGFR
SCHEMBL6265729 0.79 ALK (0.61) FLT1AURKAKDRFGFR1PDGFRB
SCHEMBL6271689 0.78 ALK (0.60) FLT1AURKAKDRFGFR1PDGFRB
SCHEMBL6268984 0.78 ALK (0.65) AURKAKDRFGFR1PDGFRBEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US claimed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US claimed
US-20140221455-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR Verva Pharmaceuticals, Inc. (AU) 2014-08-07 US disclosed
US-20050282733-A1 Differentiation modulating agents and uses therefor VERVA PHARMACEUTICALS PTY LTD (AU) 2005-12-22 US disclosed
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US disclosed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US disclosed
WO-2002096361-A2 5-ARALKYLSULFONYL-3- (PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. (US) 2002-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282733-A1 Differentiation modulating agents and uses therefor FGF1, FABP4, FGF2 FLT1 565/4885AURKA 4579/4885KDR 1077/4885
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS DMPK, ADK, MAP3K20 FLT1 661/4885AURKA 273/4885KDR 398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.